Get to know our team!
Dr. Thomas Shaw-Stiffel
Dr Thomas Shaw-Stiffel is a native of Montreal and received his MDCM from McGill in 1981. He then completed his post-grad training at the University of Toronto in Internal Medicine, Gastroenterology, as well as Clinical Pharmacology. In 1991, Dr Shaw-Stiffel moved to the United States where he held a variety of leadership positions, including Chief of GI at Bridgeport Hospital – Yale New Haven Health System, in Connecticut, Medical Director of Liver Transplantation at the University of Rochester, and later also at the University of Pittsburgh, one of the busiest liver transplant centers in the world with over 250 liver transplants a year. In 2000, he completed a Masters of Medical Management (MMM) at Tulane University, sponsored by the American College of Physician Executives. In 2007 Dr Shaw-Stiffel returned to Canada to join The Ottawa Hospital – University of Ottawa where he served as Chief of GI from 2007-2010.
Dr. Shaw-Stiffel has received several teaching and research awards. His current research interests include fatty liver (NAFLD), pre- and post-liver transplant.
Dr. Erin Kelly
Dr Erin Kelly has recently been appointed to the Department of Medicine in the division of Gastroenterology and Hepatology as an Assistant Professor. She obtained her B. Sc and medical degree at McGill University. She completed residency training in Internal medicine and sub-specialty training in Gastroenterology at the University of Ottawa. She pursued additional training in Advanced Hepatology at the University of California, San Francisco (UCSF) and a Masters in Clinical Trials through the London School of Heath and Tropical Medicine (London, UK).
Dr Kelly practices general Gastroenterology and Hepatology at the Ottawa Hospital, General Campus. Her research interests include assessment and modulation of fibrosis in patients with chronic liver disease.
Dr. Angela Cheung
Dr Angela Cheung is an Assistant Professor with The Ottawa Hospital and an Associate Scientist with the Ottawa Hospital Research Institute. As a clinical hepatologist and researcher, she has an interest in treating and improving our understanding chronic liver disease and related cancers, with a particular interest in autoimmune liver disease. She completed her medical school training at the University of Alberta and then finished her Internal Medicine training at Queen’s University. After completing a Gastroenterology fellowship and a Clinical Associate role at the University of Toronto, Dr. Cheung completed a two-year research program at the Mayo Clinic with a focus in primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), investigating the role of epigenetics and exposomics in the pathogenesis of PSC and PBC. She is a member of international and national consortia for autoimmune liver disease (AILD), including CANAL, the Canadian consortium for AILD.
Her research focus includes understanding the causes of liver disease, particularly AILD, in order to develop new treatments and biomarkers for these diseases. She has a particular interest in the microbiome, exposomics and metabolomics as well as the use of machine learning to improve discoveries in multi-omic research. She is also interested in developing risk scores to help patients and providers understand the risk of outcomes. She is also interested in working closely with patients and patient advocacy groups to help improve the diagnosis and care of patients with liver disease.
